Group 1 - The company has made progress in its share repurchase plan, announcing updates for both A-shares and H-shares [1] - The A-share repurchase plan was approved on December 24, 2024, with a total repurchase amount set between 600 million yuan and 1 billion yuan, and a maximum repurchase price of 45.00 yuan per share [2] - As of September 30, 2025, the company repurchased 15,376,845 A-shares, accounting for 1.70% of the total share capital, with a total expenditure of approximately 570.23 million yuan [2] Group 2 - The company received authorization on May 29, 2025, to repurchase H-shares through the Hong Kong Stock Exchange, with the repurchase price capped at 5% above the average closing price of the previous five trading days [3] - Specific details regarding the quantity and amount of H-shares repurchased have not yet been disclosed [3] - The company will comply with relevant regulations and fulfill its information disclosure obligations [3]

Core Viewpoint - Lijun Pharmaceutical (01513) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - The company plans to repurchase 71,400 A-shares at a total cost of RMB 2.9911 million [1] - The buyback price ranges from RMB 41.78 to RMB 41.99 per share [1] Financial Implications - The total expenditure for the buyback reflects the company's strategy to enhance shareholder value [1]